|
|
|
Insider
Information: |
Shabet Rose Sharon |
Relationship: |
|
City: |
Greenwich |
State: |
CT |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
18 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
410,181,155 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$3,576,767,232 |
|
|
Total
Shares |
410,181,155 |
|
|
Total
Value |
$3,576,767,232 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
4
|
Stock
price went up :
|
1
|
1
|
Stock
price went down : |
0
|
3
|
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
Percentage
Gain/Loss : |
183.9%
|
-32.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Arbutus Biopharma Corp |
ABUS |
10% Owner |
|
0 |
2017-07-01 |
16,013,540 |
Premium* |
|
Sio Gene Therapies Inc |
SIOX |
10% Owner |
|
0 |
2019-03-18 |
105,952,381 |
Premium* |
|
Myovant Sciences Ltd. |
MYOV |
10% Owner |
|
0 |
2019-06-04 |
40,765,599 |
Premium* |
|
Urovant Sciences Ltd. |
UROV |
10% Owner |
2018-10-01 |
0 |
2019-06-19 |
22,860,013 |
Premium* |
|
Adaptive Biotechnologies Corp |
ADPT |
10% Owner |
|
0 |
2020-12-14 |
29,993,708 |
Premium* |
|
Bridgebio Pharma, Inc. |
BBIO |
|
2019-06-27 |
0 |
2023-07-18 |
25,120,991 |
Premium* |
|
Zentalis Pharmaceuticals, Llc |
ZNTL |
10% Owner |
|
0 |
2020-12-01 |
3,943,284 |
Premium* |
|
4d Molecular Therapeutics Inc. |
FDMT |
|
2020-12-15 |
0 |
2024-01-04 |
4,247,914 |
Premium* |
|
Rallybio Corp |
RLYB |
10% Owner |
2021-07-29 |
0 |
2021-07-29 |
4,194,777 |
Premium* |
|
Figs, Inc. |
FIGS |
10% Owner |
2021-09-02 |
0 |
2021-09-03 |
14,742,689 |
Premium* |
|
Procept Biorobotics Corp |
PRCT |
|
|
0 |
2021-09-14 |
308,142 |
Premium* |
|
Ginkgo Bioworks Holdings, Inc |
DNA |
|
|
0 |
2022-03-02 |
51,055,144 |
Premium* |
|
Amylyx Pharmaceuticals, Inc. |
AMLX |
|
2022-01-11 |
0 |
2022-01-11 |
2,300,000 |
Premium* |
|
Frazier Lifesciences Acquisition... |
FLAC |
|
2022-11-02 |
0 |
2022-11-02 |
1,211,582 |
Premium* |
|
Rayzebio, Inc. |
RYZB |
|
2023-09-19 |
0 |
2024-02-26 |
0 |
Premium* |
|
Api Group Corp |
APG |
|
2024-01-02 |
0 |
2024-06-17 |
27,032,516 |
Premium* |
|
Fluidigm Corp |
FLDM |
|
|
0 |
2024-03-18 |
58,651,170 |
Premium* |
|
Inhibrx Biosciences, Inc. |
INBX |
|
|
0 |
2024-05-29 |
1,787,705 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
70 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ABUS |
Arbutus Biopharma Corp |
10% Owner |
|
2017-07-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
16,013,540 |
|
- |
|
SIOX |
Sio Gene Therapies Inc |
10% Owner |
|
2017-07-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
75,000,000 |
|
- |
|
MYOV |
Myovant Sciences Ltd. |
10% Owner |
|
2017-07-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
37,231,342 |
|
- |
|
MYOV |
Myovant Sciences Ltd. |
10% Owner |
|
2018-04-02 |
4 |
B |
$20.27 |
$22,500,004 |
I/I |
1,110,015 |
38,341,357 |
1.5 |
- |
|
SIOX |
Sio Gene Therapies Inc |
10% Owner |
|
2018-06-05 |
4 |
B |
$1.75 |
$25,000,000 |
I/I |
14,285,714 |
89,285,714 |
1.5 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2018-10-01 |
4 |
B |
$14.00 |
$37,499,994 |
I/I |
2,678,571 |
22,703,669 |
1.5 |
- |
|
SIOX |
Sio Gene Therapies Inc |
10% Owner |
|
2018-12-18 |
4 |
B |
$1.00 |
$10,000,000 |
I/I |
10,000,000 |
99,285,714 |
1.5 |
- |
|
SIOX |
Sio Gene Therapies Inc |
10% Owner |
|
2019-03-18 |
4 |
B |
$1.50 |
$10,000,001 |
I/I |
6,666,667 |
105,952,381 |
1.5 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-16 |
4 |
AB |
$6.79 |
$36,718 |
I/I |
5,408 |
22,709,077 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-17 |
4 |
AB |
$7.36 |
$45,641 |
I/I |
6,200 |
0 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-20 |
4 |
AB |
$7.98 |
$80,525 |
I/I |
10,000 |
0 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-21 |
4 |
AB |
$9,995.00 |
$99,900,025 |
I/I |
9,995 |
22,735,272 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-22 |
4 |
AB |
$8.06 |
$40,558 |
I/I |
5,033 |
22,740,305 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-23 |
4 |
AB |
$7.76 |
$37,252 |
I/I |
4,802 |
0 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-23 |
4 |
AB |
$7.76 |
$37,252 |
I/I |
4,802 |
22,745,107 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-24 |
4 |
AB |
$7.70 |
$29,233 |
I/I |
3,796 |
22,748,903 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-28 |
4 |
AB |
$7.68 |
$29,245 |
I/I |
3,807 |
22,752,710 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-29 |
4 |
AB |
$7.55 |
$51,983 |
I/I |
6,882 |
22,759,592 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-30 |
4 |
AB |
$7.97 |
$58,090 |
I/I |
7,251 |
22,766,843 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-31 |
4 |
AB |
$7.70 |
$39,042 |
I/I |
5,071 |
22,771,914 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-03 |
4 |
AB |
$7.71 |
$41,815 |
I/I |
5,424 |
22,777,338 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-04 |
4 |
AB |
$7.59 |
$56,911 |
I/I |
7,500 |
22,784,838 |
0 |
- |
|
MYOV |
Myovant Sciences Ltd. |
10% Owner |
|
2019-06-04 |
4 |
B |
$8.25 |
$19,999,997 |
I/I |
2,424,242 |
40,765,599 |
1.5 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-05 |
4 |
AB |
$8.02 |
$52,418 |
I/I |
6,540 |
22,791,378 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-06 |
4 |
AB |
$8.00 |
$56,621 |
I/I |
7,082 |
22,798,460 |
0 |
- |
|
70 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|